An investor, who purchased shares of Zogenix, Inc. (NASDAQ: ZGNX), filed a lawsuit over alleged violations of Federal Securities Laws by Zogenix, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Zogenix, Inc. (NASDAQ: ZGNX) have certain options and for certain investors are short and strict deadlines running. Deadline: June 11, 2019. NASDAQ: ZGNX investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 – 1554.
The plaintiff claims that between February 6, 2019 and April 8, 2019, the Defendants made false and/or misleading statements and/or failed to disclose that Zogenix’s NDA for FINTEPLA contained inadequate non-clinical data and an incorrect version of a clinical dataset, that consequently, Zogenix’s NDA for FINTEPLA was unlikely to gain FDA approval, and that as a result, the Company’s public statements were materially false and misleading at all relevant times.
Those who purchased shares of Zogenix, Inc. (NASDAQ: ZGNX) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.